‘Novel Approach For Retinal Disease Needs’ Stock Belite Bio Has 70% Potential Upside According To This Analyst
HC Wainwright initiated coverage on Belite Bio Inc (NASDAQ:BLTE) with a Buy rating and price target of $58 per ADS. Belite Bio…
Stealth BioTherapeutics Enters Going Private Agreement
Stealth BioTherapeutics Corp (NASDAQ:MITO) will be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd and J.…
Immutep’s Lung Cancer Candidate Shows Encouraging Efficacy As Second-Line Treatment
Immutep Limited (NASDAQ:IMMP) announced new interim data from 2nd line non-small cell lung cancer (NSCLC) patients (Part B) in the Phase…
Outset Medical Shares Jump On Resuming Tablo Hemodialysis For Home Use
The FDA cleared Outset Medical Inc’s (NASDAQ:OM) previously disclosed 510(k) submission and resumption of Tablo Hemodialysis System shipments for home use.…
Avalo Therapeutics, Apollo Therapeutics Ink Pact For Anti-IL-18 Antibody
Avalo Therapeutics Inc (NASDAQ:AVTX) and Apollo Therapeutics Group Limited have entered into a worldwide, exclusive license agreement granting rights to Apollo to research,…
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
Innate Pharma SA’s (NASDAQ:IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ:AZN) did not meet a…
FDA Removes Clinical Hold On Celyad’s Colorectal Cancer Trial
The FDA has lifted the clinical hold on Celyad Oncology SA’s (NASDAQ:CYAD) CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the company made changes…
Duchenne Gene Therapy Firm Sarepta Therapeutics’ Earns 8% Price Target Hike From This Analyst
Earlier today, Sarepta Therapeutics Inc (NASDAQ:SRPT) announced that it would submit the marketing application and seek accelerated FDA approval for SRP-9001 in…
CVS Health Sued For Taking Money From Hospitals Serving Low-Income Patients: Report
Attorney General Letitia James filed a lawsuit in New York, claiming that CVS Health Corp (NYSE:CVS) violated state antitrust law…
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.